| Huijuan Liao, | |
|
1519 144th St, Whitestone, NY 11357-3011 | |
| (631) 487-2460 | |
| Not Available |
| Full Name | Huijuan Liao |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 25 Years |
| Location | 1519 144th St, Whitestone, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023451234 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 289485 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nassau University Medical Center | East meadow, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nassau Health Care Corporation | 2961315221 | 163 |
News Archive
In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
A new study reveals that - contrary to decades of evolutionary thought - chromosome regions that are prone to breakage when new species are formed are a rich source of genetic variation.
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave™; their new microwave and parallel peptide synthesizer. The Syro Wave™ is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.
› Verified 8 days ago
| Entity Name | Nassau Health Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902822992 PECOS PAC ID: 2961315221 Enrollment ID: O20040619000043 |
News Archive
In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
A new study reveals that - contrary to decades of evolutionary thought - chromosome regions that are prone to breakage when new species are formed are a rich source of genetic variation.
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave™; their new microwave and parallel peptide synthesizer. The Syro Wave™ is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Huijuan Liao, 1519 144th St, Whitestone, NY 11357-3011 Ph: () - | Huijuan Liao, 1519 144th St, Whitestone, NY 11357-3011 Ph: (631) 487-2460 |
News Archive
In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
A new study reveals that - contrary to decades of evolutionary thought - chromosome regions that are prone to breakage when new species are formed are a rich source of genetic variation.
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave™; their new microwave and parallel peptide synthesizer. The Syro Wave™ is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.
› Verified 8 days ago
Hector M Becil, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1752 Francis Lewis Blvd, Whitestone, NY 11357 Phone: 718-746-9494 Fax: 718-746-4963 | |
Dr. Mariano Stepancic, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 15455 Willets Point Blvd, Whitestone, NY 11357 Phone: 718-886-2400 Fax: 718-886-9005 | |
Minhaj Uddin Ahmad Chowdhury, Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 14310 20th Ave, Whitestone, NY 11357 Phone: 718-961-1212 | |
Dr. Daniel J Byrns, MD Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 1470 154th St, Whitestone, NY 11357 Phone: 718-767-1818 Fax: 718-767-5306 | |
Nasrin Akter, Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 15715 19th Ave, Whitestone, NY 11357 Phone: 860-877-5933 | |
Ayman Z Attia-alla, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1752 Francis Lewis Blvd, Whitestone, NY 11357 Phone: 718-746-9494 Fax: 718-746-4963 |